Aeterna Zentaris teams with Ventana in cancer personalized medicine pact
This article was originally published in Scrip
Executive Summary
Canadian drug maker Aeterna Zentaris is partnering with Roche subsidiary Ventana Medical Systems to develop a companion diagnostic for the immunohistochemical determination of luteinizing hormone-releasing hormone (LHRH) receptor expression for AEZS-108, a doxorubicin LHRH targeted conjugate.